Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.14)
# 2,683
Out of 4,784 analysts
103
Total ratings
44.44%
Success rate
-6.41%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: In-Line | $20 → $15 | $8.03 | +86.80% | 7 | Mar 4, 2025 | |
| MCK McKesson | Maintains: Outperform | $650 → $675 | $668.06 | +1.04% | 5 | Feb 6, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $240 → $260 | $159.21 | +63.31% | 12 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $67.14 | -3.19% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $11.19 | +7.24% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $230.02 | +15.21% | 4 | Jan 7, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: In-Line | $20 | $14.93 | +33.96% | 7 | Jan 7, 2025 | |
| CAH Cardinal Health | Upgrades: Outperform | $140 | $136.44 | +2.61% | 6 | Jan 7, 2025 | |
| WAY Waystar Holding | Maintains: Outperform | $32 → $36 | $37.83 | -4.84% | 4 | Nov 7, 2024 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $9 | $8.09 | +11.25% | 2 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $265 | $177.39 | +49.39% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $4.55 | +119.78% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $58.51 | -23.09% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $4.49 | -10.91% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $16.97 | +35.53% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: In-Line | $165 | $167.33 | -1.39% | 2 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $22.59 | -11.47% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $12.38 | +112.04% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $6.58 | +127.96% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $3.40 | +223.53% | 2 | Jan 4, 2022 |
Fortrea Holdings
Mar 4, 2025
Maintains: In-Line
Price Target: $20 → $15
Current: $8.03
Upside: +86.80%
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $668.06
Upside: +1.04%
Align Technology
Feb 6, 2025
Maintains: Outperform
Price Target: $240 → $260
Current: $159.21
Upside: +63.31%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $67.14
Upside: -3.19%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.19
Upside: +7.24%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $230.02
Upside: +15.21%
DENTSPLY SIRONA
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $14.93
Upside: +33.96%
Cardinal Health
Jan 7, 2025
Upgrades: Outperform
Price Target: $140
Current: $136.44
Upside: +2.61%
Waystar Holding
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $37.83
Upside: -4.84%
Teladoc Health
Oct 8, 2024
Maintains: In-Line
Price Target: $8 → $9
Current: $8.09
Upside: +11.25%
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $177.39
Upside: +49.39%
Oct 8, 2024
Maintains: Outperform
Price Target: $8 → $10
Current: $4.55
Upside: +119.78%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $58.51
Upside: -23.09%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $4.49
Upside: -10.91%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $16.97
Upside: +35.53%
Aug 28, 2024
Reinstates: In-Line
Price Target: $165
Current: $167.33
Upside: -1.39%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $22.59
Upside: -11.47%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $12.38
Upside: +112.04%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $6.58
Upside: +127.96%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $3.40
Upside: +223.53%